1
|
Faria S, Duclos M, Cury F, Patrocinio H, Souhami L. Acute toxicity in patients with high-risk prostate cancer treated with stereotactic body radiation, with irradiation to the prostate and pelvic nodes. Cancer Radiother 2024; 28:159-163. [PMID: 38548531 DOI: 10.1016/j.canrad.2023.07.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Revised: 07/05/2023] [Accepted: 07/08/2023] [Indexed: 04/22/2024]
Abstract
PURPOSE Stereotactic body radiation therapy has been used for prostate cancer. However, the bulk of published studies on stereotactic body radiation therapy for prostate cancer has involved the irradiation of the prostate alone, without irradiation of the pelvic lymph nodes. We report our preliminary experience with this approach. MATERIAL AND METHODS The files of patients with biopsy-proven prostate cancer treated with stereotactic body radiation therapy in our institution were reviewed. Stereotactic body radiation was delivered with intensity modulated-volumetric arctherapy with daily image-guidance. The prostate planning target volume included the prostate plus a margin of 5mm in all directions. The pelvic planning target volume included pelvic nodes plus an expansion of 6 to 7mm in all directions. The prostate planning target volume received a total dose of 36.25Gy delivered in five fractions on alternate days. The nodal planning target volume received a dose of 25Gy in the same five fractions. Patients were followed during treatment, after 1, and 3 months and every 6 months thereafter. Gastrointestinal and genitourinary toxicity was prospectively graded according to Common Terminology Criteria for Adverse Events. RESULTS Among the 188 patients, 80 received stereotactic body radiation to the prostate and the pelvic nodes, while 108 received stereotactic body radiation to the prostate target only. Grade 2 acute gastrointestinal toxicity was 4% in both groups, and grade 2 acute genitourinary toxicity was 27% and 20% (P=0.9) for prostate only versus prostate and pelvis respectively. There was no grade 3 or higher acute gastrointestinal or genitourinary toxicity. CONCLUSION Stereotactic body radiation therapy in five fractions including the prostate and pelvic nodes, in patients with high-risk prostate cancer, has been feasible and safe in terms of acute toxicity.
Collapse
Affiliation(s)
- S Faria
- Department of Radiation Oncology, Cedars Cancer Center, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, PQ H4A3J1, Canada.
| | - M Duclos
- Department of Radiation Oncology, Cedars Cancer Center, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, PQ H4A3J1, Canada
| | - F Cury
- Department of Radiation Oncology, Cedars Cancer Center, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, PQ H4A3J1, Canada
| | - H Patrocinio
- Medical Physics Unit, McGill University, Montreal, Canada
| | - L Souhami
- Department of Radiation Oncology, Cedars Cancer Center, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, PQ H4A3J1, Canada
| |
Collapse
|
2
|
Nabid A, Carrier N, Vigneault E, Nguyen TV, Vavassis P, Brassard MA, Bahoric B, Archambault R, Vincent F, Bettahar R, Wilke DR, Souhami L. Biochemical Failure in Intermediate Risk Prostate Cancer: Then What? Long-Term Data from a Phase III Trial. Int J Radiat Oncol Biol Phys 2023; 117:e421. [PMID: 37785385 DOI: 10.1016/j.ijrobp.2023.06.1576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Aiming to determine long-term outcomes post biochemical failure (BF) in patients (pts) treated for intermediate-risk prostate cancer, we analyzed data from our prospective randomized trial (PCS III). MATERIALS/METHODS From December 2000 to September 2010, 600 pts with intermediate risk prostate cancer (IRPC) received prostate radiotherapy (RT) with or without short-term (6 months) androgen deprivation therapy (ADT) on a Phase III trial. We report death rate from prostate cancer, rate and timing of BF plus the final clinical outcome of patients, alive or dead, with BF. Chi-squared test was used to compare BF and prostate cancer progression (PCP) rates between patient with or without ADT. RESULTS Median age at randomization was 71 years (IQR 66-74). With a median follow-up (FU) of 13.5 years (IQR 11.2-17.0), 74.5% (447/600) were free from BF at last FU. Of these, 211 died, 79 stopped FU after 10 years, 9 were lost to FU, 6 withdrew from the study and 142 are still on FU, at a median follow-up of 13.2 years (IQR = 10.9 - 16.2). A total of 153 pts (25.5%) developed BF at a median time of 6.5 years post-randomization. Among BF pts, 82/153 died: we documented 32 deaths from prostate cancer (DPC) at a median time of 6 years post-BF and 50/153 pts died from other causes at a median time of 4.7 years from BF. 48/153 BF pts continue on FU: 34 show no clinical evidence of cancer, 9 developed a second cancer and 5 show clinical evidence of PCP. 20/153 pts stopped FU after 10 years: 3 of them with PCP. 3/153 pts were lost to FU: 1 after 3 years with prostate bone metastasis and 2 after 13 years of FU. In the first 5 years post-randomization, 47 pts (7.8%) presented BF with 1 (0.2%) DPC; between 6 and 10 years, there were another 84 (14%) BFs and 11 (1.8%) DPC. Finally, after 10 years and beyond, we recorded an additional 22 (3.7%) BFs and 20 (3.3%) DPC. The rate of patients who received ADT was significantly lower in patients with BF (74/153 = 48.4%) compared to patients without BF (324/447 = 72.5%), p<0.001. The rate of patients who received ADT was also significantly lower in patients with PCP (19/48 = 39.6%) compared to patients without PCP (379/552 = 68.7%), p<0.001. CONCLUSION In our trial for intermediate-risk prostate cancer, a quarter of the pts developed BF. Most of the BFs occurred between 5- and 10- year post-randomization. Deaths due to prostate cancer post-BF occurred at a median time of 6 years, justifying the need for long-term FU. BF and PCP were significantly higher in patients not receiving ADT.
Collapse
Affiliation(s)
- A Nabid
- Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada
| | - N Carrier
- Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada
| | - E Vigneault
- CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ), Québec, QC, Canada
| | - T V Nguyen
- Centre Hospitalier Universitaire de Montréal, Montréal, QC, Canada
| | - P Vavassis
- Maisonneuve-Rosemont Hospital, Montreal, QC, Canada
| | - M A Brassard
- CIUSSS du Saguenay-Lac-Saint-Jean, Chicoutimi, QC, Canada
| | - B Bahoric
- Jewish General Hospital, Montreal, QC, Canada
| | | | - F Vincent
- Centre Hospitalier Regional de Trois-Rivieres, Trois-Rivieres, QC, Canada
| | - R Bettahar
- CSSS Rimouski-Neigette, Rimouski, QC, Canada
| | - D R Wilke
- Nova Scotia Cancer Centre, Halifax, NS, Canada
| | - L Souhami
- Department of Radiation Oncology, McGill University Health Centre, Montreal, QC, Canada
| |
Collapse
|
3
|
Nabid A, Carrier N, Martin AG, Bahary JP, Vavassis P, Vass ST, Bahoric B, Archambault R, Vincent F, Bettahar R, Souhami L. Patient Reported Outcomes in High-Risk Prostate Cancer Patients with or without Testosterone Recovery after Androgen Deprivation Therapy. Int J Radiat Oncol Biol Phys 2023; 117:S95-S96. [PMID: 37784611 DOI: 10.1016/j.ijrobp.2023.06.428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) In a previous report from a randomized trial of 630 patients (pts), we showed that 18 months of androgen deprivation therapy (18m ADT) appears to be equally effective as 36 months (36m ADT) in high-risk prostate cancer (HRPC) pts. We performed the current analysis to evaluate quality of life (QOL) using the 25 items of EORTC PR25 validated tool in pts with or without testosterone (T) recovery after ADT. MATERIALS/METHODS We selectedpts with no biochemical failure to avoid subsequent T variations due to reintroduction of ADT for recurrence. Patients receiving exactly 18 or 36m of ADT, survived more than one year (y) post randomization, had T measured at baseline and during follow-up and who completed QOL questionnaire entered this review. The 25 items were regrouped into 5 scales. All items and scales scores were linearly transformed to a 0-100 points scale. Serum T was measured at baseline then at each visit. We defined unrecovered testosterone as measured below the normal level. All items and scales scores were analyzed with general linear model and repeated measures to evaluate changes between pts with or without T recovery over time. T recovery was adjusted in a multivariable model including age, initial normal/unrecovered T and ADT (18 or 36m). P-value < 0.01 was considered statistically significant and a difference in mean scores of ≥10 points was considered clinically relevant. Patient-reported outcomes were filled out before treatments, every 6m during ADT, 4m after ADT and then once a year for 5y. RESULTS Two hundred sixty nine of 630 pts met the eligibility criteria and were retained for the analysis. At a median follow-up of 14 years, 140/269 (52.0%) pts recovered T to normal level: 94/166 (56.6%) in 18m ADT and 46/103 (44.7%) in 36m ADT, p = 0.056. The median time to recovered T was significantly lower in 18m vs. 36m ADT (3.04 vs. 5.06 y, p<0.001). The global adherence to QOL questionnaires was 83.9% (2649/3156) and was similar between arms. Pts recovering T compared to those who did not, had a better QOL. 6/20 items [difficult to get enough sleep: get up frequently at night to urinate, blood in stool, hot flushes, feel less man, interested in sex, sexually active (with or without intercourse)] and 2/4 scales (treatment and sexual activity) were statistically significant (all p<0.01). 2 items were also clinically relevant: hot flushes and interested in sex. Hot flushes were clinically relevant (more than 10 point of difference) between 3.5 to 5y inclusively with maximum difference of 19.4 point. Interest in sex was clinically relevant with 13.1 point of difference at 3 years. CONCLUSION T recoverypost long-term ADT is associated with a significantly improved QOL in patients with HRPC. Considering similar prostate cancer clinical outcomes and faster T recovery, our results suggest that 18m ADT may be the most appropriate ADT treatment duration for these patients.
Collapse
Affiliation(s)
- A Nabid
- Centre hospitalier universitaire de Sherbrooke, Sherbrooke, QC, Canada
| | - N Carrier
- Centre hospitalier universitaire de Sherbrooke, Sherbrooke, QC, Canada
| | - A G Martin
- Department of Radiation Oncology CHU de Québec-Université Laval, Québec, QC, Canada
| | - J P Bahary
- Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada
| | - P Vavassis
- Maisonneuve-Rosemont Hospital, Montreal, QC, Canada
| | - S T Vass
- CSSS Chicoutimi, Chicoutimi, QC, Canada
| | - B Bahoric
- Jewish General Hospital, Montreal, QC, Canada
| | | | - F Vincent
- Centre hospitalier regional de Trois-Rivieres, Trois-Rivieres, QC, Canada
| | - R Bettahar
- CSSS Rimouski-Neigette, Rimouski, QC, Canada
| | - L Souhami
- Department of Radiation Oncology, McGill University Health Centre, Montreal, QC, Canada
| |
Collapse
|
4
|
Deek MP, Shetty A, Song Y, Efstathiou JA, Feng FY, Shipley WU, Simko J, Mouw KW, Miyamoto DT, Pollack A, Michaelson D, Zietman AL, Coen JJ, Dahl DM, Jani A, Souhami L, Chang BK, Lee RJ, Rodgers J, Tran PT. Prognostic Significance of Pretreatment Immune Cell Infiltration in Muscle Invasive Bladder Cancer Treated with Definitive Chemoradiation: Analysis of NRG RTOG 0524 and 0712. Int J Radiat Oncol Biol Phys 2023; 117:S22-S23. [PMID: 37784456 DOI: 10.1016/j.ijrobp.2023.06.278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Chemoradiation therapy (CRT) is an organ conserving approach in the treatment of locally advanced bladder cancer. Chemoradiation is thought to potentially result in immunogenic stimulation, and bladder cancer is often a tumor with high immune cell infiltration. Thus, we aimed to profile the tumor immune microenvironment of bladder cancer and identify prognostic immune biomarkers for CRT response by profiling tumor samples from NRG/RTOG 0524 and 0712, two prospective trials of CRT in muscle invasive bladder cancer (MIBC). MATERIALS/METHODS Pretreatment tissue samples from both trials were profiled using Cofactor Genomics ImmunoPrism, an RNA sequencing assay that uses gene expression profiles to quantify immune cell populations in the tumor microenvironment (TME). Differential gene expression was estimated for different immune cell type proportions across samples. Kaplan-Meier survival analysis and log rank tests were performed to evaluate differences in overall survival (OS) stratified by genes influenced by immune cell proportions or genes associated with immune response signatures. RESULTS A total of 70 samples (43 from RTOG 0524 and 27 from RTOG 0712) underwent analysis using the ImmunoPrism assay. Immune cell proportions were as follows: CD8 T cells: median 1.2%, CD4 T cells: median 0.8%, Treg cells: median 9.2%, CD19 B cells: median 5.1%, M2 macrophages: median 0.8%, M1 macrophages: median 0%. Unbiased clustering based on gene expression profiles driven by immune cell proportions demonstrated two groups: cluster 1 with a low percentage of immune cells and shorter OS (median 31 months) and cluster 2 with a high percentage of immune cells and longer OS (median 101 months, p = 0.036). Higher expression of genes associated with T cell infiltration (CD8A and ICOS) was associated with improved OS (104 vs 35 months, p = 0.028, HR = 0.48 (0.25 - 0.94), p = 0.031) as was higher expression of IDO1, which is associated with the interferon gamma pathway (104 vs 35 months, p = 0.042, HR = 0.49 (0.24 - 0.99), p = 0.046). CONCLUSION Bladder tumors have a wide range of immune cell infiltration in the TME. Increased immune cell proportions are prognostic for OS following CRT, as well as a higher expression of genes associated with T cell infiltration interferon gamma signaling. These findings have implications for the integration of immunotherapy in the definitive management of MIBC; and can be explored further in the ongoing NRG/SWOG 1806 trial.
Collapse
Affiliation(s)
- M P Deek
- Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
| | - A Shetty
- University of Maryland, Baltimore, MD
| | - Y Song
- University of Maryland, Baltimore, MD
| | - J A Efstathiou
- Department of Radiation Oncology, Harvard School of Medicine, Boston, MA
| | - F Y Feng
- Department of Radiation Oncology, University of California San Francisco, San Francisco, CA
| | - W U Shipley
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
| | | | - K W Mouw
- Broad Institute of MIT and Harvard, Cambridge, MA
| | - D T Miyamoto
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
| | - A Pollack
- Department of Radiation Oncology, University of Miami/Sylvester Comprehensive Cancer Center, Miami, FL
| | - D Michaelson
- Massachusetts General Hospital/ Harvard Medical School, Boston, MA
| | - A L Zietman
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
| | - J J Coen
- Massachusetts General Hospital, Boston, MA
| | - D M Dahl
- Massachusetts General Hospital/ Harvard Medical School, Boston, MA
| | - A Jani
- Department of Radiation Oncology, Emory University, Atlanta, GA
| | - L Souhami
- Department of Radiation Oncology, McGill University Health Centre, Montreal, QC, Canada
| | - B K Chang
- Radiation Medicine Associates, Oklahoma City, OK
| | - R J Lee
- Intermountain Medical Center, Murray, UT
| | - J Rodgers
- NRG Oncology Statistics and Data Management Center, Philadelphia, PA
| | - P T Tran
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| |
Collapse
|
5
|
Nabid A, Carrier N, Vigneault E, Brassard M, Bahoric B, Archambault R, Vavassis P, Vincent F, Bettahar R, Wilke D, Nguyen T, Martin A, Bahary J, Duclos M, Vass S, Souhami L. Cardiovascular Causes of Death in Patients Treated for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
6
|
Baydoun A, Sun Y, Sandler H, Bolla M, Nabid A, Denham J, Jia A, Zaorsky N, Garcia J, Brown J, Jackson W, Dess R, Efstathiou J, Feng F, Maingon P, Steigler A, Souhami L, Berlin A, Kishan A, Spratt D. Efficacy of Bicalutamide Monotherapy in Prostate Cancer: A Network Meta-Analysis of 10 Randomized Trials. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
7
|
Zaorsky N, Sun Y, Nabid A, Zapatero A, Bolla M, Denham J, Pisansky T, Sandler H, Efstathiou J, Maingon P, Steigler A, Souhami L, Carrier N, Armstrong J, Jackson W, Jia A, Ma T, Romero T, Kishan A, Spratt D. Optimal Duration of Androgen Deprivation Therapy (ADT) with Definitive Radiotherapy for Prostate Cancer: An Individual Patient Data (IPD) Meta-Analysis from the International MARCAP Consortium. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.460] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
8
|
Shenouda G, Petrecca K, Abdulkarim B, Owen S, Panet-Raymond V, Diaz R, Guiot M, Carvalho T, Charbonneau M, Hall J, Souhami L. Comparison of Two Phase II Trials of Neoadjuvant Temozolomide Followed with Concomitant and Adjuvant Temozolomide and Hypofractionated Accelerated Radiotherapy with or without Metformin in Patients with Newly Diagnosed Glioblastoma. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.449] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
9
|
McDonald A, DeMora L, Lenzie A, Hoyle J, Yang E, Michalski J, Parliament M, Bahary J, Hurwitz M, III M, Spratt D, Mishra M, Valicenti R, Lau H, Souhami L, Mendez L, Chen Y, Doncals D, Feng F, Sandler H. Body Composition and Risk of All-Cause Mortality in Men Treated With Radiation Therapy for Prostate Cancer: A Pooled Analysis of NRG/RTOG 9406 and NRG/RTOG 0126. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
10
|
Marcq G, Evaristo G, Kool R, Shinde-jadhav S, Skowronski R, Mansure J, Souhami L, Cury F, Brimo F, Kassouf W. Impact de l’expression de Pd-l1 au sein du microenvironnement tumoral sur les résultats oncologiques de la thérapie trimodale pour cancer de vessie infiltrant le muscle. Prog Urol 2021. [DOI: 10.1016/j.purol.2021.08.120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
11
|
Patrick HM, Souhami L, Kildea J. Reduction of inter-observer contouring variability in daily clinical practice through a retrospective, evidence-based intervention. Acta Oncol 2021; 60:229-236. [PMID: 32988249 DOI: 10.1080/0284186x.2020.1825801] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
BACKGROUND Inter-observer variations (IOVs) arising during contouring can potentially impact plan quality and patient outcomes. Regular assessment of contouring IOV is not commonly performed in clinical practice due to the large time commitment required of clinicians from conventional methods. This work uses retrospective information from past treatment plans to facilitate a time-efficient, evidence-based intervention to reduce contouring IOV. METHODS The contours of 492 prostate cancer treatment plans created by four radiation oncologists were analyzed in this study. Structure volumes, lengths, and DVHs were extracted from the treatment planning system and stratified based on primary oncologist and inclusion of a pelvic lymph node (PLN) target. Inter-observer variations and their dosimetric consequences were assessed using Student's t-tests. Results of this analysis were presented at an intervention meeting, where new consensus contour definitions were agreed upon. The impact of the intervention was assessed one-year later by repeating the analysis on 152 new plans. RESULTS Significant IOV in prostate and PLN target delineation existed pre-intervention between oncologists, impacting dose to nearby OARs. IOV was also present for rectum and penile-bulb structures. Post-intervention, IOV decreased for all previously discordant structures. Dosimetric variations were also reduced. Although target contouring concordance increased significantly, some variations still persisted for PLN structures, highlighting remaining areas for improvement. CONCLUSION We detected significant contouring IOV in routine practice using easily accessible retrospective data and successfully decreased IOV in our clinic through a reflective intervention. Continued application of this approach may aid improvements in practice standardization and enhance quality of care.
Collapse
Affiliation(s)
- H. M. Patrick
- Medical Physics Unit, McGill University, Montreal, Canada
| | - L. Souhami
- Department of Oncology, McGill University Health Centre, Montreal, Canada
| | - J. Kildea
- Medical Physics Unit, McGill University, Montreal, Canada
- Department of Oncology, McGill University Health Centre, Montreal, Canada
| |
Collapse
|
12
|
Marcq G, Souhami L, Cury F, Salimi A, Aprikian A, Tanguay S, Vanhuyse M, Rajan R, Brimo F, Mansure J, Kassouf W. Étude de phase I évaluant l’administration concomitante de l’atezolizumab à la thérapie trimodale pour patients atteints d’un cancer de vessie localisé infiltrant le muscle. Prog Urol 2020. [DOI: 10.1016/j.purol.2020.07.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
13
|
Coen J, Rodgers J, Saylor P, Lee C, Wu C, Parker W, Lautenschlaeger T, Zietman A, Efstathiou J, Jani A, Kucuk O, Souhami L, Sandler H, Shipley W. Bladder Preservation with Twice-Daily Radiation plus 5-Flourouracil/Cisplatin or Daily Radiation plus Gemcitabine for MIBC – Updated Results of NRG/RTOG 0712: A Randomized Phase 2 Trial. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.2122] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
14
|
Mell L, Pugh S, Jones C, Nelson T, Morginstin M, Gore E, Zakeri K, Bahary J, Souhami L, Michalski J, Hartford A, Mishra M, Roach M, Parliament M, Choi K, Pisansky T, Husain S, Malone S, Horwitz E, Feng F. Effect Of Hormone Therapy Within Risk Groups Defined By Generalized Competing Event Model: Ancillary Analysis Of NRG Oncology’s RTOG 9408. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.435] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
15
|
Nabid A, Carrier N, Martin AG, Bahoric B, Wilke D, Vigneault E, Vincent F, Bahary JP, Brassard MA, Duclos M, Vavassis P, Bettahar R, Archambault R, Vass S, Nguyen T, Souhami L. Guideline for testosterone recovery in localized prostate cancer treated with different ADT duration: Long-term data from two prospective randomized trials. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)32718-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
16
|
Marcq G, Kool R, El-Achkar A, Brimo F, Vanhuyse M, Aprikian A, Tanguauy S, Cury F, Souhami L, Kassouf W. Résultats oncologiques de la thérapie trimodale pour cancer de vessie infiltrant le muscle. Prog Urol 2019. [DOI: 10.1016/j.purol.2019.08.228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
17
|
Kucharczyk M, Tsui J, Bahoric B, Souhami L, Niazi T. Prostate Bed Radiotherapy Intensification with Long Term Androgen Deprivation and Pelvic Nodal Radiotherapy Is Effective and Well Tolerated: Results from the McGill 0913 Phase II Clinical Trial. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
18
|
Nabid A, Carrier N, Vigneault E, Nguyen-Huynh T, Vavassis P, Brassard M, Bahoric B, Archambault R, Vincent F, Bettahar R, Wilke D, Souhami L. Outcomes Based on Risk Factors in Intermediate Risk Prostate Cancer: a Secondary Analysis of a Randomized Phase III Trial. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
19
|
Coates J, Jeyaseelan A, Ybarra N, Tao J, David M, Faria S, Souhami L, Cury F, Duclos M, Naqa I. SP-0011 Unified Radiogenomic Prediction of Late Radiotherapy Toxicities. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)30431-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
20
|
Jones C, Pugh S, Sandler H, Chetner M, Amin M, Efstathiou J, Den R, Leibenhaut M, Longo J, Bahary J, Rosenthal S, Souhami L, Michalski J, Hartford A, Amin P, Roach M, Yee D, Rodgers J, Shipley W. Long-Term Update of NRG Oncology RTOG 94-08. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.06.062] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
21
|
Alrashidi S, Souhami L, Cury F, Vanhuyse M, Aprikian A, Duclos M, Rajan R, Tanguay S, Faria S, Kassouf W. Bladder-Sparing Hypofractionated Intensity Modulated Radiation Therapy plus Weekly Gemcitabine in Patients with Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.444] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
22
|
Faria S, Cury F, Duclos M, Souhami L. Hypofractionated Intensity Modulated Radiation Therapy to Prostate and Pelvic Nodes Plus Androgen Suppression in High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.06.354] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
23
|
Shenouda G, Souhami L, Petrecca K, Owen S, Panet-Raymond V, Carvalho T, Guiot M, Abdulkarim B. A Phase 2 Trial of Neoadjuvant Temozolomide (TMZ) Followed By Accelerated Hypofractionated Radiation Therapy (AHRT) and TMZ Followed By Adjuvant TMZ in Patients with Newly Diagnosed Glioblastoma (GBM): Long Term Survival and Toxicity Analysis. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.06.096] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
24
|
Shipley W, Zhang P, Saylor P, Lee C, Wu C, Parker W, Lautenschlaeger T, Zietman A, Efstathiou J, Jani A, Kucuk O, Souhami L, Rodgers J, Sandler H, Coen J. OC-0057: Randomized phase 2 trial of radiation with either gemcitabine or 5FU/cisplatin in bladder cancer. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)30367-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
25
|
Coen J, Zhang P, Saylor P, Lee C, Wu C, Parker W, Lautenschlaeger T, Zietman A, Efstathiou J, Jani A, Souhami L, Kucuk O, Rodgers J, Sandler H, Shipley W. Selective Bladder Preservation with Twice-Daily Radiation Plus 5-Flourouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Patients with Muscle Invasive Bladder Cancer—Primary Results of NRG/RTOG 0712: A Randomized Phase 2 Multicenter Trial. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.09.019] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
26
|
Adil K, Popovic M, Cury F, Faria S, Souhami L. Anisotropic Bladder Planning Target Volume is Adequate When Using Cone Beam Computed Tomography as a Form of Image Guided Radiation Therapy. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
27
|
Nabid A, Marie-Pierre G, Vigneault E, Souhami L, Lemaire C, Brassard M, Bahoric B, Archambault R, Vincent F, Bettahar R, Wilke D, Nguyen-Huynh T, Martin A, Bahary J, Duclos M, Vass S. Significance of Testosterone Suppression in Localized Prostate Cancer Treated with Androgen Deprivation Therapy and Radiotherapy: Data from 2 Phase 3 Trials. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.307] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
28
|
Shakir S, Souhami L, Petrecca K, Mansure J, Panet-Raymond V, Shenouda G, Singh K, Alodaini A, Abdulkarim B, Guiot M. PV-0502: Post-operative radiation therapy in atypical meningiomas: analysis of prognostic factors. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)30942-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
29
|
Turgeon GA, Souhami L, Kopek N, Hirsh V, Ofiara L, Faria SL. Thoracic irradiation in 3weeks for limited-stage small cell lung cancer: Is twice a day fractionation really needed? Cancer Radiother 2017; 21:89-98. [PMID: 28325618 DOI: 10.1016/j.canrad.2016.09.015] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2016] [Revised: 09/07/2016] [Accepted: 09/11/2016] [Indexed: 12/12/2022]
Abstract
PURPOSE Many Canadian institutions treat limited-disease small cell lung cancer with 40Gy in 15 fractions delivered once-a-day in 3weeks concomitantly with chemotherapy. This regimen is convenient and seems to be effective. Here, we report and compare with a literature review the outcomes of patients with limited-stage small cell lung cancer treated in our institution with this hypofractionated regimen. PATIENTS AND METHODS From January 2004 to December 2012, patients with limited-stage small cell lung cancer treated curatively with platinum-based chemotherapy and concurrent thoracic radiotherapy at a dose of 40Gy in 16 fractions once-a-day were eligible for this review. RESULTS Sixty-eight patients fit the analysis criteria, including ten patients with small pleural effusion. The median age was 66years old. After a median follow-up of 77months for those alive, the median survival was 28months. At 3 and 5years respectively, the locoregional control rates were 67 and 64%, while the overall survival rates were 40 and 35%. Prophylaxis cranial irradiation was delivered to 68% of the patients. Grade 2 and 3 acute esophagitis occurred in respectively 49 and 9% of the patients. There was no grade 4 radiation-induced toxicity. All patients, except for one, completed their thoracic irradiation course without interruption. CONCLUSION Once-a-day hypofractionated radiation with concurrent chemotherapy followed by prophylactic cranial irradiation is a practical regimen. Based on our experience and the published literature, it appears to be similarly effective as regimens using twice-daily fractionation in 3weeks, or once-daily in 6 to 7weeks with higher radiotherapy doses. Further prospective comparisons of hypofractionation with the current recommendations are needed.
Collapse
Affiliation(s)
- G A Turgeon
- Department of Oncology, Division of Radiation Oncology, McGill University Health Centre, 1001 Decarie Boulevard, H4A 3J1 Montreal, Quebec, Canada
| | - L Souhami
- Department of Oncology, Division of Radiation Oncology, McGill University Health Centre, 1001 Decarie Boulevard, H4A 3J1 Montreal, Quebec, Canada
| | - N Kopek
- Department of Oncology, Division of Radiation Oncology, McGill University Health Centre, 1001 Decarie Boulevard, H4A 3J1 Montreal, Quebec, Canada
| | - V Hirsh
- Department of Oncology, Division of Medical Oncology, McGill University Health Centre, 1001 Decarie Boulevard, H4A 3J1 Montreal, Quebec, Canada
| | - L Ofiara
- Division of Respiratory Medicine, McGill University Health Centre, 1001 Decarie Boulevard, H4A 3J1 Montreal, Quebec, Canada
| | - S L Faria
- Department of Oncology, Division of Radiation Oncology, McGill University Health Centre, 1001 Decarie Boulevard, H4A 3J1 Montreal, Quebec, Canada.
| |
Collapse
|
30
|
Loblaw A, Pickles T, Crook J, Martin AG, Vigneault E, Souhami L, Cury F, Morris J, Catton C, Lukka H, Cheung P, Sethukavalan P, Warner A, Yang Y, Rodrigues G. Stereotactic Ablative Radiotherapy Versus Low Dose Rate Brachytherapy or External Beam Radiotherapy: Propensity Score Matched Analyses of Canadian Data. Clin Oncol (R Coll Radiol) 2017; 29:161-170. [DOI: 10.1016/j.clon.2016.10.001] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2016] [Revised: 08/25/2016] [Accepted: 09/22/2016] [Indexed: 02/05/2023]
|
31
|
Shakir S, Souhami L, Petrecca K, Mansure J, Khushdeep S, Panet-Raymond V, Shenouda G, Al Odaini A, Abdulkarim B, Guiot M. Analysis of Prognostic Factors for Local Recurrence in Atypical Meningiomas. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.787] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
32
|
Nabid A, Carrier N, Vigneault E, Souhami L, Lemaire C, Brassard M, Bahoric B, Archambault R, Vincent F, Nguyen T. Second Malignancies as First Cause of Death in Localized Prostate Cancer Treated With Radiation Therapy: Data from Two Phase 3 Trials. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
33
|
Mendez L, Moraes F, Suh J, Taunk N, Souhami L, Slotman B, Weltman E, Marta G. Trial Sponsorship and Self-Reported Conflicts of Interest in Clinical Trials of Central Nervous System Malignancies. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.885] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
34
|
Moraes F, Mendez L, Suh J, Taunk N, Souhami L, Slotman B, Weltman E, Marta G. Funding Source, Self-Reported Conflicts of Interest, and the Interpretation of Conclusions of Phase 1, 2, and 3 Trials in Neuro-Oncology. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
35
|
Shipley W, Seiferheld W, Lukka H, Major P, Heney N, Grignon D, Sartor O, Patel M, Bahary J, Zietman A, Pisansky T, Zeitzer K, Lawton C, Feng F, Lovett R, Balogh A, Souhami L, Rosenthal S, Kerlin K, Sandler H. Report of NRG Oncology/RTOG 9601, A Phase 3 Trial in Prostate Cancer: Anti-androgen Therapy (AAT) With Bicalutamide During and After Radiation Therapy (RT) in Patients Following Radical Prostatectomy (RP) With pT2-3pN0 Disease and an Elevated PSA. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2015.10.048] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
36
|
Nabid A, Carrier N, Vigneault E, Souhami L, Lemaire C, Brassard M, Bahoric B, Archambault R, Vincent F, Nguyen T. Radiation Therapy With or Without Short-Term Androgen Deprivation Therapy in Intermediate-Risk Prostate Cancer: Results of a Phase 3 Trial. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2015.10.038] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
37
|
Bruner DW, Deshmukh S, Michalski J, Purdy J, Bosch W, Bahary J, Patel M, Parliament M, Lock M, Lau H, Hamstra D, Fisher S, Souhami L, Kwok Y, Seider M, Vigneault E, Gay H, Rosenthal S, Sandler H, Movsas B. Bowel and Bladder Function of Men on a Phase 3 Randomized Study of High Versus Standard Dose of 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
38
|
Turgeon G, Kopek N, Souhami L, Hirsh V, Ofiara L, Faria S. Small Cell Lung Cancer Limited Disease (LSCLC): Are Long Treatments With Higher Doses Really Needed? Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.1621] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
39
|
Rodrigues G, Wang T, Warner A, Pickles T, Crook J, Martin A, Vigneault E, Cury F, Souhami L, Morris W, Catton C, Lukka H. Post–Biochemical Failure Risk Stratification to Predict Survival in Prostate Cancer: A Recursive Partitioning Analysis. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.1039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
40
|
Vassilakopoulou M, Won M, Curran W, Souhami L, Prados M, Langer C, Rimm D, Hanna J, Neumeister V, Melian E, Diaz A, Atkins J, Brady L, Schultz C, Howard S, Dicker A, Knisely J. BRCA1 Protein Expression Predicts Survival in Glioblastoma Multiforme (GBM) Patients From a RTOG Cohort. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.335] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
41
|
Neto OSB, Faria S, Cury F, David M, Duclos M, Shenouda G, Souhami L. Intermediate-Risk Prostate Cancer Treated With Hypofractionated External Beam Radiation Therapy Alone: Long-term Outcomes. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.1107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
42
|
Barbosa Neto O, Souhami L, Faria S. Hypofractionated radiation therapy for prostate cancer: The McGill University Health Center experience. Cancer Radiother 2015; 19:431-6. [DOI: 10.1016/j.canrad.2015.05.015] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2015] [Revised: 05/19/2015] [Accepted: 05/20/2015] [Indexed: 10/23/2022]
|
43
|
Bell EH, Pugh S, Gilbert M, Mehta M, Klimowicz A, Magliocco A, Bredel M, Robe P, Grosu A, Stupp R, Curran W, Corn B, Brown P, Glass J, Souhami L, Jeffrey Lee R, Brachman D, Deutsch M, Won M, Chakravarti A. BI-12 * RTOG 0525 RECURSIVE PARTITIONING ANALYSIS BASED ON CLINICAL AND PROTEIN BIOMARKER PARAMETERS. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou239.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Faria S, Cury F, Duclos M, Souhami L. Radiation Therapy-Induced Castration in Men With Advanced Prostate Cancer: Results of a Prospective Phase 1 Study. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
45
|
Sabit K, Panet-Raymond V, Souhami L, El Naqa I, Shenouda G, Zeitouni A, Sirhan D. Volumetric Growth Measurements of Pituitary Macroadenomas Following Surgical Resection and Indications for Early Adjuvant Radiation Therapy. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
46
|
Lecavalier-Barsoum M, Souhami L, Cury F, Duclos M, Faria S. Pelvic Lymph Nodes Displacement in High-Risk Prostate Cancer Patients Treated With Image-Guided IMRT With 2 Independent Target Volumes. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1373] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
47
|
Mitin T, George A, Zietman A, Kaufman D, Uzzo R, Dreicer R, Heney N, Wallace H, Souhami L, Dobelbower M, Sandler H, Shipley W. Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder Preserving Combined Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of RTOG 9906 and 0233. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
48
|
Nabid A, Carrier N, Martin A, Bahary J, Souhami L, Duclos M, Vincent F, Vass S, Bahoric B, Archambault R, Lemaire C. Quality of Life in Patients with Testosterone Recovery after Long Term Androgen Deprivation Therapy for High Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.101] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
49
|
Pham H, Hu C, Michaelson M, Dahl D, Wu C, Whittington R, Swanson G, Vuky J, Lee R, Souhami L, Chang B, George A, Sandler H, Shipley W. The Initial Report of RTOG 0524: Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone with Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates With Muscle-Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.581] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
50
|
Coates J, Jeyaseelan K, Ybarra N, David M, Faria S, Souhami L, Cury F, Duclos M, El Naqa I. Sci-Thur AM: YIS - 02: Radiogenomic Modeling of Normal Tissue Toxicities in Prostate Cancer Patients Receiving Hypofractionated Radiotherapy. Med Phys 2014. [DOI: 10.1118/1.4894887] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|